XVIPF (Xvivo Perfusion AB) 6-Month Price Index: 1.40 (As of Jul. 03, 2026)


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $41.71
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB 6-Month Price Index?

Xvivo Perfusion AB XVIPF -1.32% 91 6-Month Price Index is 1.40 as of Jul. 03, 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.71 (Significantly Undervalued). The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-03), Xvivo Perfusion AB's 6-Month Price Index is 1.40.

Xvivo Perfusion AB  (OTCPK:XVIPF) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Xvivo Perfusion AB 6-Month Price Index Related Terms

XVIPF vs ABT, SYK, MDT: 6-Month Price Index Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB  (OTCPK:XVIPF) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.40 mean?
Xvivo Perfusion AB (XVIPF) has a 6-Month Price Index of 1.40 as of Jul. 03, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's 6-Month Price Index too high?
Xvivo Perfusion AB's current 6-Month Price Index is 1.40. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 6-Month Price Index compare to ABT and SYK?
Xvivo Perfusion AB's 6-Month Price Index of 1.40 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current 6-Month Price Index is 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.71, compared to a current price of $29.00 — trading 30.5% below its estimated fair value. The current 6-Month Price Index is 1.40. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 6-Month Price Index is 1.40 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 30.5% below its estimated GF Value™ of $41.71. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • 6-Month Price Index: 1.40
  • GF Value™: $41.71 vs. price of $29.00 (30.5% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$41.71
GF Value